CB1400, Patented By Canopus BioPharma, Prevents Tumor Growth And Enhances The Anti-Tumor Effects Of Cisplatin And Cetuximab (Erbitux)
Canopus BioPharma, Inc. (OTC: CBIA), has confirmed the efficacy of its oncology candidate, CB1400, as a tumor reducing agent and has also demonstrated the synergistic effect of this drug in combination with both cisplatin and cetuximab (Erbitux) in two mice lung cancer models. Chairman of Canopus BioPharma, Dr.
More: continued here
Filed under: Lung Cancer on June 30th, 2008